Throughout 2025, MFN-like concepts were diffuse background noise. That volume intensified in Q4, when legislative and regulatory conversations crystallized around concrete constructs.

With its looming fruition, MFN is no longer an election cycle talking point that faded before implementation. Focus is centered on actions such as tying U.S. net prices or Medicare reimbursement to international reference baskets, “top 6” or “top 12” country averages, or even lowest-price anchors. This winter’s global policy debates in Davos confirmed that high‑margin, low‑empathy industries remain irresistible targets. In that context, MFN is less of a U.S. political quirk and more of a local expression of a global affordability backlash.

Two key factors precipitated this change:

MFN was increasingly framed not as experimental, but as a baseline expectation in some corners of the policy community. Certainty emerged around the notion that MFN will exist in some form unless industry offers credible alternatives.
Political logic hardened in the face of persistent affordability concerns and high-profile launches. MFN-style approaches became an easy shorthand for “taking on drug prices,” regardless of downstream impact on innovation or access.

For companies that treated MFN as a recurring scarecrow, late 2025 should have been a wake-up call. This is no longer just a rulemaking risk, it is a strategic environment.

Three Gs of demonstrations: GENEROUS, GUARD, GLOBE

Layered atop MFN rhetoric is a new class of large-scale demonstration threats. While often framed with reassuring acronyms, they carry severe structural implications for pricing, access, and negotiation dynamics. While each proposed model is different in scope and mechanism, they share several features:

They aim to benchmark or compress drug prices across therapeutic areas, often through international reference, negotiated ceilings, or discount floors.
They introduce population-level or geographic experiments that could quickly become de facto standards, especially if they touch high-spend categories like oncology, autoimmune, or rare disease treatments including cell or gene therapies.
They create data-driven leverage for policymakers. Once a demonstration is up and running, early results can justify permanence or expansion, even if the underlying design is blunt. This will worsen if mid-terms result in a divided government, as the Administration will increase its use of Centers for Medicare and Medicaid Innovation (CMMI) authority, solely within its purview.

GENEROUS, GUARD, and GLOBE are less important as acronyms than as signals. They show policymakers are now comfortable testing models that:

Move beyond product-by-product tweaks,
Make net price visibility less private, and
Use Medicare’s purchasing and demonstration authority to shape the entire commercial price architecture.

For pharma, the risk is not just lower prices. It’s losing control of the logic by which value is defined and rewarded.

JP Morgan 2026: Insights from between the lines

At JP Morgan this year, very few CEOs led with MFN. However, it was subtly ubiquitous in careful phrasing, hedged long-term guidance, and repeated references to “policy headwinds” and “pricing discipline.” This narrative, toggling between cautious optimism and quiet anxiety, put pharma and bio leadership on notice. Three themes stood out to me:

Portfolio tilting toward protected and specialty spaces. Many companies emphasized assets with clear clinical differentiation, smaller populations, or strong unmet need. The implicit bet: Even in an MFN or demonstration-heavy world, truly transformative therapies for oncology, rare disease, or severe chronic conditions will retain some pricing power if launched from day one with robust evidence and thoughtful contracting.
Growing emphasis on “total value” and system economics. Presentations leaned heavily on reductions in hospitalizations, procedures, or downstream costs. That’s not new, but the urgency is. Executives understand that if the debate is only about list price, MFN logic wins. If the narrative expands to avoided surgeries, reduced complications, and productivity gains, there is more room to negotiate alternatives to crude reference benchmarks.
Quiet experimentation with alternative payment and global launch strategies. Behind the main stage, there was significant discussion about:

– Launch sequencing to avoid early low-price anchors in ex‑U.S. markets;

– Outcomes-based arrangements that can coexist with or substitute for MFN-style formulas, and;

– Internal capabilities for real-world data, indication-based pricing, and contracts that can survive greater transparency.

In short, JP Morgan 2026 reflected an industry recognizing the MFN and demo threats are real, while not yet fully adjusting operating models in response.

Priorities for CEOs and executive teams

The first weeks of 2026 have clarified one thing: Hoping MFN goes away is not a strategy. Policy risk is now a core part of commercial strategy, not an afterthought. From podiums in the U.S. and abroad this January, leaders describe policy as a standing business model feature, not a series of “storms” to ride out.

Pharma is no exception: MFN, GENEROUS, GUARD, and GLOBE are simply the healthcare manifestations of this new reality. For CEOs and leadership teams, a few priorities are advisable:

Build an MFN‑aware global pricing and launch strategy.

– Stop treating U.S. and ex‑U.S. pricing as silos. Map how early EU or other market prices would flow through hypothetical MFN constructs and pressure U.S. net prices over time.

– Factor MFN risk into launch sequencing and trade-offs: Sometimes delaying or reframing a low-price launch ex‑U.S. may protect long-term U.S. value.

– Scenario-plan for “soft MFN” (reference ranges, guardrails) as well as “hard MFN” (direct pegging), and understand which assets remain viable under each scenario.

Redefine “value story” as a cross-functional discipline.

– Elevate market access, health economics, and policy into the earliest phases of R&D and BD decision-making.

– Treat value communication not as a slide deck, but as an integrated package including trial design, endpoints, real‑world evidence, and contracting constructs that can withstand demonstration scrutiny.

– For high-stakes therapies (cell, gene, bispecifics, rare disease), pressure-test whether your evidence truly supports the price in a world of increased benchmarking and demonstrations (not just today’s environment).

Engage, don’t just react, on demonstrations

– Take seriously GENEROUS/GUARD/GLOBE-style models even before they are finalized; contribute credible alternatives that protect access while addressing genuine budget and affordability concerns.

– Partner with patient groups, providers, and payers to design demonstration alternatives rewarding outcomes, adherence, and appropriate use, rather than just blunt list-price cuts.

– Prepare with practical implementation guidance: Policymakers are more likely to listen when industry demonstrates how to make a workable, patient-centered model, not just how a proposal is flawed.

Invest in internal “policy‑analytics” muscle

– Build or strengthen teams capable of simulating impacts of MFN and demos across portfolios, channels, and timelines.

– Integrate claims, EHR, and real‑world data to quantify therapy impacts on total cost of care. This is your best defense against more aggressive pricing models.

– Use these analytics not only as price defense, but also to design contracts and pilots aligned with incentives across stakeholders.

The Playbook: Shift from MFN fear to strategic readiness

The real question for 2026 is not how MFN, GENEROUS, GUARD, or GLOBE will land. It’s whether pharma leaders will seize this time to modernize value-creation, -pricing, and -defense.

CEOs and executive teams who treat MFN as a recurring “policy storm” remain on their heels, chasing rules, reacting to demonstrations, and negotiating from fear. Those who treat it as a forcing function will:

Build launch strategies that anticipate reference pressures;
Align evidence, access, and pricing from day one;
Shape, rather than merely survive, the next generation of demonstrations; and
Focus on threats in a three-dimensional manner, not just from the Administration but from the halls of Congress (Trump’s MFN, codified in law) and even from within (inaction or business-as-usual from market access, pricing, or global leadership less concerned than the C-Suite about the present environment)

In an MFN world, those taking the fewest policy risks will not win. Success will come to those turning policy awareness into a core strategic capability and keeping the focus where it belongs – squarely on sustainable access and real value for patients.

A note to market access leadership

The MFN and demo wave is a career‑defining moment. You are no longer just negotiators of price, but architects of how innovation, evidence, and policy intersect. Those leaning into co‑designing alternatives, managing portfolio‑level policy risks, and translating global pricing choices into U.S. realities will help their companies not just withstand MFN, but use it to modernize value creation and defense.

Get in touch to see how ADVI can help you move beyond price negotiation and start building the cross-functional muscle needed to lead through this policy wave.